SCHEMBL6094437

SCHEMBL6094437

COc1ccc(C(C)NC(=O)c2nc(N3CCCCS3(O)O)n(C)c(=O)c2O)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 2/20 0.39
PHGDH O43175 1/20 0.38
ACACB O00763 4/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 2/20 0.38
PDE2A O00408 3/20 0.37
CNR2 P34972 2/20 0.37
ADORA2A P29274 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
MCHR1 Q99705 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
KCNK3 O14649 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
CNR1 P21554 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6094424 0.91 PHGDH (0.41) CLK1PHGDHACACBTP53MAPT
SCHEMBL6093763 0.90 L3MBTL1 (0.37) PHGDHTP53MAPTPDE2ATDP1
SCHEMBL6096240 0.90 POLB (0.42) MAPT
SCHEMBL6095162 0.89 SMN1; SMN2 (0.38) PHGDHTP53MAPTPDE2AMCHR1
SCHEMBL6094125 0.89 ALDH1A1 (0.40) CLK1PHGDHACACBPDE2AKCNK3
SCHEMBL6095582 0.89 MAOA (0.43) PHGDHPDE2ACNR2MEN1NPC1
SCHEMBL6095839 0.89 ALDH1A1 (0.45) PHGDHTP53MAPTADORA2AMEN1
SCHEMBL6095305 0.89 ALDH1A1 (0.45) PHGDHTP53MAPTADORA2AMEN1
SCHEMBL6094063 0.87 MEN1 (0.42) PHGDHPDE2ACNR2MEN1KMT2A
SCHEMBL6097061 0.84 MAPT (0.44) TP53MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US claimed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US claimed
US-7135467-B2 Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-14 US disclosed
US-20040204498-A1 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204498-A1 HIV integrase inhibitors IMPDH1, TYMP, REV1 CLK1 3572/4885PHGDH 1699/4885ACACB 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.